PARSIPPANY, N.J. / May 01, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team. Zoetis will provide an update on the company’s strategy to deliver long-term profitable growth and value for shareholders, followed by a Q&A session.
The event will begin at 9:00 a.m. ET and conclude at approximately 12:30 p.m. ET. A live webcast of the investor day presentations, along with supporting materials, will be available to the general public on the day of the event on the Zoetis Investor Relations website. Information on pre-registering for the webcast is available today.
In-person attendance is by invitation only and advance registration is required. Institutional investors and analysts interested in attending should contact one of the company’s Investor Relations contacts listed on this press release.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.
Last Trade: | US$156.40 |
Daily Change: | 1.61 1.04 |
Daily Volume: | 1,325,722 |
Market Cap: | US$69.310B |
May 06, 2025 February 14, 2025 February 13, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load